EGFR and non-small cell lung carcinoma: In early 2021, a pooled analysis of five phase II prospective clinical trials included 124 patients (mainly Asiatic) affected by stage I–IIIA EGFR mutant NSCLC who underwent neoadjuvant erlotinib or gefitinib treatment.